Profund Advisors LLC Acquires 17,525 Shares of Vaxcyte, Inc. $PCVX

Profund Advisors LLC raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 53.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 50,447 shares of the company’s stock after acquiring an additional 17,525 shares during the quarter. Profund Advisors LLC’s holdings in Vaxcyte were worth $2,328,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. ProShare Advisors LLC raised its holdings in Vaxcyte by 10.4% in the fourth quarter. ProShare Advisors LLC now owns 26,725 shares of the company’s stock worth $1,233,000 after purchasing an additional 2,524 shares during the period. DNB Asset Management AS boosted its position in shares of Vaxcyte by 46.6% during the fourth quarter. DNB Asset Management AS now owns 16,471 shares of the company’s stock worth $760,000 after buying an additional 5,235 shares during the period. Swiss Life Asset Management Ltd acquired a new position in shares of Vaxcyte during the fourth quarter worth about $249,000. Nan Fung Trinity HK Ltd. boosted its position in shares of Vaxcyte by 37.1% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 142,930 shares of the company’s stock worth $6,595,000 after buying an additional 38,680 shares during the period. Finally, Values First Advisors Inc. acquired a new position in shares of Vaxcyte during the fourth quarter worth about $216,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction on Friday, May 1st. The shares were sold at an average price of $56.83, for a total value of $127,867.50. Following the completion of the sale, the chief operating officer directly owned 160,744 shares of the company’s stock, valued at approximately $9,135,081.52. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of Vaxcyte stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total transaction of $180,000.00. Following the completion of the sale, the chief accounting officer directly owned 28,975 shares of the company’s stock, valued at approximately $1,738,500. This trade represents a 9.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 17,037 shares of company stock valued at $994,899. Insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the topic of several analyst reports. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Guggenheim reiterated a “buy” rating and issued a $116.00 price target on shares of Vaxcyte in a research note on Monday, February 2nd. Finally, BTIG Research upped their price target on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Stock Performance

PCVX stock opened at $48.78 on Wednesday. Vaxcyte, Inc. has a 52-week low of $29.08 and a 52-week high of $65.00. The company has a fifty day moving average price of $57.09 and a 200-day moving average price of $52.35. The company has a market capitalization of $7.04 billion, a P/E ratio of -7.09 and a beta of 1.30.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the prior year, the business posted ($1.04) EPS. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -7.85 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.